introduction Cotrimoxazole (CTX) should be given to all HIV-infected adults with mild or severe HIV-disease or those with CD4 counts below 350/mm 3 according to 2006 WHO guidelines. We assessed the impact of CTX prophylaxis on the risk of malaria episodes in HIV-1-infected adults from four West African countries with different patterns of malaria transmission.
Introduction
In 2015, 60% of the 214 million cases of malaria worldwide occurred in sub-Saharan Africa, where 26 million of the 36.7 million HIV-infected individuals live [1, 2] . This strong overlap between malaria and HIV displays some heterogeneicity [3, 4] . For instance, transmission of malaria is unstable in East or Southern Africa compared to Western or central regions, while the former has a much higher HIV-prevalence [4] [5] [6] . Although the attributable mortality of malaria is much higher in young children, recent reports suggested increasing frequency and severity of Plasmodium falciparum infection among older children and adults living in African urban settings who also happen to bear the highest HIV-prevalence [7] [8] [9] .
Malaria and HIV can influence each other's pathogenisis. HIV infection increases the risk of malaria acquisition and its severity, with a more pronounced effect as immunosuppression becomes more severe [10] [11] [12] [13] . Malaria episodes are associated with transient lymphopenia and a decrease in CD4+ cell count among individuals with increased levels of HIV RNA replication [14] [15] [16] . These negative effects must be dealt with by reinforcing interventions against both diseases [17] .
In HIV-infected persons living in tropical areas, malaria is one of the targets of cotrimoxazole (CTX) prophylaxis, together with invasive bacterial diseases, pneumocystosis, toxoplasmosis and isosporosis. In the era prior to antiretroviral therapy (ART), a randomised controlled trial in Côte d'Ivoire demonstrated that CTX prophylaxis decreased by 90% the risk of malaria episodes in HIVinfected adults [18] . These findings were further confirmed in studies performed in East Africa, where a reduction in clinical malaria with CTX in HIV-infected adults and children ranged from 40% to 95%, when accounting for the effect of Insecticide-treated bednets (ITNs) [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Based on this evidence, WHO recommended in 2006 that CTX should be given to all HIV-infected adults with CD4 cell counts below 350/mm 3 and/or at WHO clinical stage 2-4 [30] , and then revised the guidelines in 2014 to recommend initiating CTX regardless of CD4 cell count and WHO stage in settings where malaria and/or severe bacterial infections were highly prevalent [31] . However, some unresolved issues remain regarding malaria and CTX in HIV-infected individuals. Firstly, most of the national guidelines still recommend starting CTX when CD4 cells count is below 350 cells/mm 3 , even in settings with high malaria burden [30] . Secondly, national recommendations are hardly applied in the field, where many HIV-infected patients eligible for CTX prophylaxis still do not receive it [32] . Thirdly, most of the evidence for CTX prophylaxis efficacy against malaria in West Africa was obtained in the pre-ART era. In this region, CTX prophylaxis was recommended as early as 2000, after the results of the randomised trials in Côte d'Ivoire [18] were published. Some authors then hypothesised that largescale use of CTX might accelerate parasitic resistance and limit its efficacy in the long term [22, 33] .
The aim of this study was to assess the impact of CTX prophylaxis on the risk and severity of malaria episodes in HIV-1-infected adults from four West African countries with different patterns of malaria transmission.
Methods

Study design and settings
MALHIV was a multicentre cohort study conducted between September 2007 and March 2010 in four West African cities: Abidjan (Côte d'Ivoire), Bamako (Mali), Bobo-Dioulasso (Burkina Faso) and Dakar (Senegal). The study protocol was approved by national ethics committees of the countries. Study centres were Infectious and Tropical Disease Departments at university teaching hospitals within each city.
Study participants
Eligibility criteria were as follows: HIV-1 infection, at least 18 years old, no ongoing CTX or other sulfamide treatment, ART-na€ ıve and no concomitant self-medication. Exclusion criteria were patients with HIV-2 monoinfection or dually reactive HIV-1/2 infection, any acute infectious episode, first trimester of pregnancy, history of allergy to sulfamides, haemoglobin level <7.5 g/ml, and neutrophil count <750 cells/ml. All patients gave written informed consent before inclusion.
Enrolment and follow-up
Patients enrolled in the study were requested to complete a baseline visit at enrolment, and then every 12 weeks. Between scheduled visits, patients had free access to the study centre in case of fever or other symptoms. Sociodemographic, ITN use and clinical data were recorded at baseline. At each visit, clinical data, including symptoms of malaria, were assessed. Adherence to ART and CTX was measured by pill count. Adverse events were graded in accordance with the WHO grading table [34] . Severe morbidity other than malaria was defined as the occurrence of any WHO stage 3 or 4 defining HIV-disease or any clinical event leading to at least one day of hospitalisation and/or death.
Treatment of HIV and malaria
Patients initiated CTX (800 mg sulfamethoxazole and 160 mg trimethoprim, once daily) at enrolment (CTX group) if they were symptomatic for HIV ( ), or if they had a plasma HIV RNA >10 5 copies/ml. The latter criterion was included in the study protocol, although it was not included in the national guidelines in any of the countries.
Two clinical forms of malaria were distinguished: uncomplicated malaria, defined by fever without clinical or biological severity criteria, and severe malaria, defined by fever with at least one major criterion of severity according to WHO definition [36] .
Based on national guidelines, patients with an uncomplicated malarial episode received a fixed-dose combination of artesunate plus amodiaquine (AS 200 mg/ AQ 50 mg , one pill BID for three consecutive days) as first-line treatment, or a fixed-dose combination of artemether plus lumefantrine (A 120 mg L 20 mg , four pills BID for three consecutive days) as an alternative. In the event of severe malaria, intravenous infusion of quinine (8 mg/8 h per day for 5-7 days) was prescribed as first-line treatment, or intramuscular artemether (2.4 mg/12 h for 5-7 days) as an alternative. The efficacy of antimalarial treatment was evaluated according to WHO 28 day-protocol [37] . In case of treatment failure, merozo€ ıte proteins 1 and 2 (msp1 and msp2) genotyping were performed to distinguish recurrence from new infection [38] .
For women who became pregnant during follow-up and were already on CTX prophylaxis, CTX was maintained and no other treatment was given. If the woman had no eligibility criteria for CTX, she received a prophylaxis with proguanil+atovaquone in fixed-dose combination [30] .
Laboratory procedures
Biological tests, including complete blood count, liver and renal function tests, CD4 counts, plasma HIV viral load, thick and thin blood smears (Giemsa Stain), were performed at enrolment and every six months. CD4 cells were counted by FACS Count Flow cytometer (Fascan Becton-Dickinson, San Carlos, CA, USA). Plasma HIV-1 RNA levels were quantified using the Amplicor 1.5 Roche assay (Rotkreuz, Switzerland), detection threshold 50 copies/ml or the Abbott Real Time HIV-1 m2000rt quantitative assay (Abbott Laboratories, Chicago, IL, USA, detection threshold 40 copies/ml).
Patients who presented with documented fever (axillary temperature ≥37.5°C) or history of fever in the previous 24 h had a finger prick for thick and thin blood smears for Plasmodium species detection. Thick smears were screened for the presence of malaria parasites according to WHO procedures. Parasite density was estimated by counting the number of asexual parasites per 200 white blood cells (WBC) and was expressed as the number of parasites per microlitre (ll) of blood. Parasite species were confirmed by Plasmodium small subunit ribosomal RNA (ssrRNA) gene amplification using nested-PCR as previously described [38] .
If the smear was positive for any Plasmodium sp parasite, the patient was considered as having malaria regardless of parasite density. For every confirmed case of malaria, the 2003-revised WHO 28-day evaluation protocol for antimalarial drug efficacy was applied. It included clinical examination, thick blood smears on days 0, 1, 2, 3, 14, 21 and 28 after treatment initiation, other biological tests (complete blood cell counts, liver and renal function tests) on days 0, 14 and 28 and CD4 count and HIV viral load measurements on days 0 and 28.
Statistical analysis
Patients were analysed in two groups, defined by the prescription (CTX group) or absence of prescription (non-CTXgroup) of CTX at enrolment. For patients who were not prescribed CTX at enrolment (non-CTX group) and who started CTX later, follow-up was censored at the date of the first CTX prescription. For patients who were not prescribed ART at inclusion and who started ART later, follow-up was censored at the date of the first ART prescription. Analyses were performed on intent-totreat basis, meaning that all patients from CTX group were considered receiving CTX during their entire follow-up period.
For baseline characteristics, comparisons between groups were performed using Student's t-test, Mann-Whitney U test or variance analysis for continuous variables, and chi-square test or Fisher's exact test for categorical variables.
The rate of malaria was estimated with its 95% confidence interval (CI). The rate was calculated as the number of patients having at least one incident episode of malaria per 100 person-years (PY) of 'at-risk follow-up'. The 'at-risk period' began at baseline and ended at the earliest among the following events: first malaria episode, death, lost to follow-up, CTX initiation (for non-CTX group only), ART initiation (for patients who did not start ART at baseline only) or end of study (at month-18).
Multivariable Cox's proportional hazard regression method was used to compare the risk of malaria between CTX groups, adjusting for baseline CD4 count, ART, HIV viral load, WHO clinical stage and any other variables found to be associated with the risk of malaria with a P < 0.25 in univariable analysis. Adjusted hazard ratios (aHR) were reported with 95% CI. P-values were two-sided. Analyses were performed using SAS software version 9.1 (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
A total of 514 patients were enrolled: 184 (35.8%) in Bobo-Dioulasso, 157 (30.5%) in Abidjan, 99 (19.3%) in Bamako and 74 (14.4%) in Dakar. Overall, 347 (67.5%) were in CTX group and 167 (32.5%) in non-CTX group. The proportion of patients in CTX group was similar across sites (range 62.6-72.3%). ART was initiated at inclusion in 261 (50.8%) patients overall, 245 (70.6%) in CTX group and 16 (9.6%) in non-CTX group (P < 0.01). All first-line ART regimens were composed of two nucleos(-t)ide reverse transcriptase inhibitors (NRTI), combined with a non-nucleos(-t)ide reverse transcriptase inhibitor (NNRTI, n = 243, 93.1%), a third NRTI (n = 14, 5.4%), or a protease inhibitor (n = 4, 1.5%). Compared to patients in the CTX group, those in the non-CTX group were younger (P ˂ 0.01), were more frequently women (P = 0.02), had higher CD4 cell count (P ˂ 0.01), and lower HIV viral load (P ˂ 0.01) ( Table 1) .
Follow-up
Participants were followed for a total of 583 person-years (median 15.3 months, Interquartile range (IQR): 10.1-18.0). Of the 167 patients in CTX group, 28 started CTX during follow-up after a mean of 8.8 months. At Reasons for follow-up being censored were as follows: CTX and/or ART initiation (n = 109), transfer to another centre (n = 11), voluntary withdrawal from the study (n = 9) or loss to follow-up (n = 82) ( Table 1) .
Incidence of malaria
Of the 154 episodes of fever, 50 (32.4%) were confirmed as malaria episodes among 42 patients (CTX group, n = 17; non-CTX group, n = 25). One episode that occurred in a pregnant woman in the non-CTX group was classified as severe. All other episodes were classified as uncomplicated. Plasmodium falciparum was the only species identified. The mean parasitaemia was 55724 per ll (standard deviation 141701) in the CTX group and 15671 per ll (standard deviation 27163) in the non-CTX group (P = 0.83). The median time between enrolment and first malaria episode was 12.1 months (IQR 4.0-17.8) overall, 12.0 months (IQR 3.0-17.9) in the CTX group and 12.1 months (IQR 6.5-17.7) in the non-CTX group (P = 0.22). The incidence of malaria was 8.7/100 PY (95%CI 6.3-11.5) overall, with substantial variation across the four cities ( Table 2 ). The incidence of malaria was lower in the CTX group (5.2/100 PY) than in the non-CTX group (15.5/100 PY) (Incidence Rate ratio [IRR] 0.36, 95%CI 0.15-0.80, P < 0.01). The cumulative probability of remaining free of malaria at month-18 was 88.1% overall (95%CI 83.3-91.6); 93.3% in the CTX group (95%CI 88.3-96.2) vs. 77.2% (95%CI 65.1-85.6) in the non-CTX group (logrank: P < 0.0001) ( Figure 1a) ; and 93.0% in patients who started ART at enrolment (95%CI 88.0-96.0) vs. 79.2% in those who did not start ART at enrolment (95%CI 67.7-87.0) (log-rank: P = 0.02) (Figure 1b) .
In multivariate analysis (Table 3) 
Antimalarial treatment efficacy and tolerance
In the only case of severe malaria, intravenous quinine was administered. All other patients were given AS/AQ. In these AS/AQ-treated patients, the median time to fever clearance was 48 h (IQR 24-72), and the PCR-adjusted adequate clinical and parasitological response by Day 28 was 98.1% (95%CI 89.6-99.9). One case of late treatment failure was observed at Day 21, but was reclassified as reinfection after PCR adjustment. AS/AQ was well tolerated, with grade 3-4 neutropenia occurring in four (9.5%) patients: three were in the CTX group and received concomitant ART with zidovudine, and one was in the non-CTX group and did not received zidovudine.
Discussion
Our data clearly suggest that CTX prophylaxis still has a protective effect against malaria in West African HIVinfected individuals, particularly for those living in stable transmission area. As expected, patients in the CTX group at baseline had an adjusted risk of malaria three timeslower than those in the non-CTX group. In the four West African countries, CTX was recommended when CD4 fell below 350 cells/mm 3 . This was based on the results of two CTX placebo-controlled trials performed in Côte d'Ivoire at the end of the 1990s [30, 39, 40] . One of these trials clearly demonstrated that malaria was one of the diseases prevented by CTX [39] . During the 2000s, many studies conducted in eastern and southern Africa, confirmed that CTX had a strong preventive effect on malaria in HIV-infected adults and children [19, 20, 22-24, 27, 29] . In two four-year cohorts of HIV-infected adults in Uganda and Malawi, CTX prophylaxis reduced malaria incidence from 51 to 9 episodes per 100 PY, with an additional reduction to 3.5 and 2.1 per 100 PY when ART and bednets were further introduced [41] .
Having low-CD4 cell count number and living in an area of unstable transmission have been previously reported to be associated with malaria severity [11, 12, 42] . This differs from our findings, where most of the episodes occurred in areas of stable transmission (Burkina Faso and Cote d'Ivoire), and were observed in patients with CD4 counts above 350 cells/mm 3 . Moreover we did not observe severe malaria cases even in the cities with unstable transmission.
Drops in CD4 cell counts during malaria episodes have been previously reported in HIV-infected patients [14, 15] . Our study confirms this phenomenon. The most important conclusion to be drawn from it in the field is that any change in CD4 counts in a context of concomitant acute malaria should clearly not be interpreted as a sign of non-adherence or ART failure. In our study, the concentration of plasma HIV RNA decreased between baseline and malaria episode while it increased in a study conducted in rural Malawi [15] . This difference could be explained by several factors. Firstly, the median time between enrolment and first malaria episode was higher in our study (12 months vs. 4 months). Thus, the baseline HIV RNA in our study does not reflect the pre-malaria measurement. Secondly, in our study, 40% of those who had at least one malaria episode were on ART while no patient was on ART in the other study. Indeed, ART might diminish the effect of malaria on HIV RNA concentrations. After the malaria episode, the concentration of plasma HIV-RNA decreased in our study as reported in the previous studies [14, 15] . As expected, artesunate-amodiaquine combination therapy was efficacious [43, 44] . Unlike in previous studies, we did not observe any delay in clinical response and parasitaemia clearance. AS/AQ combination was well tolerated, even when patients received ART. The only grade 3 or 4 adverse events were neutropenia. They were rare and transient. Severe neutropenia with AS/AQ was previously reported as more frequent in HIV-infected children receiving ART as compared to HIV-negative ones [45] . We did not observe severe liver toxicity, even among patients exposed to NNRTI, contrary to previous report of increased hepatotoxicity with concomitant use of amodiaquine with NNRTI [46] .
Our study has some limitations. First, the sample size was small, especially in the CTX group. However, the association between CTX use and a lower risk of malaria was strong. Second, only three cases of malaria were observed in the area of unstable transmission. This did not allow us to assess CTX efficacy by transmission area. Third, we compared two groups with very different baseline characteristics. However, patients who received CTX had more advanced HIV-disease, suggesting that the study might have been biased towards an underestimation of the protective effect of CTX against malaria, rather than an overestimation. Fourth, the follow-up duration only allows us to draw medium term conclusions. Fifth, we could not document the prevalence of resistance -conferring Plasmodium falciparum mutations. These mutations, in case of presence, could have the effect of underestimating the efficacy of CTX. Despite these limitations, this study has two main strenghts. First, it took place in four West African countries with different transmission patterns of malaria. Second, few patients who did not start CTX at baseline started it afterwards. This allowed us to compare the incidence of malaria between patients who started CTX prophylaxis at enrolment and those who were followed-up with no CTX prophylaxis.
Conclusion
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